mGlu2 Negative Allosteric Modulators for Selective CNS Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for selective modulators of metabotropic glutamate receptor 2 (mGlu2) to address various diseases and disorders such as depression, anxiety, obsessive-compulsive disorder, cognitive disorders, Alzheimer's disease, and autism spectrum disorders, as existing modulators lack specificity and efficacy.
Innovation Solution
Development of negative allosteric modulators (NAMs) of mGlu2, which selectively bind to allosteric sites to modulate mGlu2 activity, thereby inhibiting processes associated with mGlu2 dysfunction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing modulators are used to target mGlu2, then some therapeutic effect may be achieved, but selectivity and efficacy are insufficient
Solution Approach 1:
The patent applies local quality by designing compounds with specific structural features (substituted isoindolinone core with particular R1-R6 groups) that confer selective binding to mGlu2 receptor. The molecular structure is optimized with specific substituents (fluoro, alkyl, aryl, heteroaryl groups) at defined positions to enhance selectivity for mGlu2 over other receptors, directly addressing the selectivity deficiency of existing modulators.
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular parameters including substituent types (halogen, alkyl, aryl, heteroaryl), substituent positions (R1-R6 on the isoindolinone core), and molecular configuration to optimize both selectivity and efficacy. The structure-activity relationship studies involve changing these chemical parameters to achieve compounds with improved therapeutic profiles for multiple disorders.
2Reliability
If selective mGlu2 modulators are developed, then specificity and efficacy improve, but development complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the complex molecule into distinct functional segments: a core isoindolinone structure (providing mGlu2 binding capability) and various substituent groups (R1-R6) that can be independently optimized. This modular approach allows systematic development of selective modulators by combining a validated core structure with different substituent patterns, managing complexity through structured design rather than random screening.
3Reliability
If negative allosteric modulators are used to inhibit mGlu2 activity, then therapeutic benefits are achieved for various disorders, but the mechanism requires high precision binding
Solution Approach 1:
The patent applies local quality by introducing specific functional groups at precise positions on the isoindolinone core (R1-R6 substituents) that create complementary interactions with specific amino acid residues in the mGlu2 allosteric site. This localized optimization of molecular features ensures high-precision binding required for negative allosteric modulation, achieving therapeutic benefits through exact molecular recognition.
Data Source
AI summary
Described are 6-aryl isoindolin-1-ones as negative allosteric modulators of metabotropic glutamate receptor 2 (mGlu2), pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treating depression, anxiety, obsessivecompulsive disorder, cognitive disorders, Alzheimer's disease, or autism spectrum disorders in a subject.